Purine analogs for the treatment of low-grade lymphoproliferative disorders

Oncologist

Volumn 1, Issue 3, 1996, Pages 125-139

  Fidias, Panos ^a   Chabner, Bruce A ^a   Grossbard, Michael L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cladribine; Hairy cell leukemia; Leukemia chronic lymphocytic; Lymphoma non hodgkin's; Pentostatin; Vidarabine analogs

Indexed keywords

EID: 0343838472     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.1-3-125     Document Type: Article

References (15)

1. Ezdinli EZ, Andersen JR, Melvin F et al. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 1985;3:769-775.
2. Keating MJ, Scouros M, Murphy S et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988;2:157-164.
3. Parlier Y, Gorin NC, Najman A et al. Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas - a report of 131 cases. Cancer 1982;50:401-409.
4. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995;86:2463-2474.
5. Giblett ER, Anderson JE, Cohen F et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972;2:1067-1069.
6. Adams A, Harkness RA. Adenosine deaminase activity in thymus and other human tissues. Clin Exp Immunol 1976;26:647-649.
7. Van der Weyden MB, Kelley WN. Human adenosine deaminase. Distribution and properties. J Biol Chem 1976;251:5448-5456.
8. O'Dwyer PJ, Wagner B, Leyland-Jones B et al. 2′-Deoxycoformycin (Pentostatin) for lymphoid malignancies. Ann Intern Med 1988;108:733-743.
9. Amer ES, Flygar M, Bohman C et al. Deoxycytidine kinase is constitutively expressed in human lymphocytes: consequences for compartmentation effects, unscheduled DNA synthesis, and viral replication in resting cells. Exp Cell Res 1988;178:335-342.
10. Jackson RC, Leopold WR, Ross DA. The biochemical pharmacology of (2′-R)-chloropentostatin, a novel inhibitor of adenosine deaminase. Adv Enzyme Regul 1986;25:125-139.
11. Hershfield MS, Kredich NM, Ownby DR et al. In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine in adenosine deaminase-deficient patients. J Clin Invest 1979;63:807-811.
12. Hershfield MS, Kredich NM, Koller CA et al. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2′-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine. Cancer Res 1983;43:3451-3458.
13. Kefford RF, Helmer MA, Fox RM. S-adenosylhomocysteine hydrolase inhibition in deoxyadenosine-treated human T-lymphoblasts and resting peripheral blood lymphocytes. Cancer Res 1982;42:3822-3827.
14. Lee N, Russell N, Ganeshaguru K et al. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase. Br J Haematol 1984;56:107-119.
15. Carson DA, Wasson DB, Kaye J et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980;77:6865-6869.